Table 5.
Outcome of APAC treatment.
| 2020 cohort | 2021 control | Statistical value | P-value | |
|---|---|---|---|---|
| Affected eyes, n | 64 | 51 | ||
| IOP at follow up (mm Hg); mean ± SD | 13.21 ± 3.54 | 12.79 ± 3.28 | t = 0.65 | 0.26 |
| CDVA at follow up (LogMar) | 0.48 ± 0.52 | 0.26 ± 0.21 | t = 2.84 | 0.00 |
| Percentage with blindness (≤ Snellen VA 3/60) |
21.87% (14/64) | 7.84% (4/51) | X2= 4.23 | 0.03 |
| PD (mm) | 5.47 ± 1.62 | 4.33 ± 1.27 | t = 4.12 | 0.00 |
| C/D at follow up | 0.47 ± 0.51 | 0.38 ± 0.32 | t = 0.49 | 0.31 |
| Percentage with GON, % (n) | 31.25% (20/64) | 13.73% (7/51) | X2= 4.85 | 0.03 |
| Cornea edema at follow up, grade, n (%) | X2= 2.02 | 0.15 | ||
| Grade 1 | 50 (78.12%) | 45 (88.24%) | ||
| Grade 2 | 14 (21.88%) | 6 (11.76%) | ||
| Grade 3 | 0 | 0 |